NorthWest Biotherapeutics Inc (NWBO)

[sharpie510]

The report linked below in Nature says only 3-4% living at 5 years under SOC and the majority of those are IDH mutant -- CLOSE TO ZERO are IDH wild-type (and if they are, maybe they are pseudo-progressors).

But if 25-35% of the primary glioblastoma IDH wild-type patients in the DCVax-L phase 3 clinical trial treatment arm are living to 5 years on DCVax-L (newly diagnosed), that is A MAJOR IMPROVEMENT. I bet a good chunk of the recurrent primary glioblastoma patients from the placebo arm who crossed over to DCVax-L are also living much longer than their RCT counterparts.

It seems that NWBO will analyze these non glioblastoma patients (IDH mutant) separately from the true glioblastoma patients (IDH wild-type). And in doing so, the RCT data for those with true glioblastoma will show even poorer survival results and the DCVax-L treated data will show even better survival results.

https://www.nature.com/articles/s41598-020-68011-4

Twenty-three populations from 63 potentially eligible studies contributed to the meta-analyses. Pooled 2-year overall survival estimates for the earlier and later study periods were 9% (95% confidence interval [CI] 6–12%; n/N?=?1,488/17,507) and 18% (95% CI 14–22%; n/N?=?5,670/32,390), respectively. Similarly, pooled 3-year survival estimates increased from 4% (95% CI 2–6%; n/N?=?325/10,556) to 11% (95% CI 9–14%; n/N?=?1900/16,397). One study with a within-population comparison showed similar improvement in survival among the older population. Pooled 5-year survival estimates were 3% (95% CI 1–5%; n/N?=?401/14,919) and 4% (95% CI 2–5%; n/N?=?1,291/28,748) for the earlier and later periods, respectively. Meta-analyses of real-world data suggested a doubling of 2- and 3-year survival in glioblastoma patients since 2005. However, 5-year survival remains poor with no apparent improvement. Detailed clinically annotated population-based data and further molecular characterization of longer-term survivors may explain the unchanged survival beyond 5 years.